ASX Linkedin Twitter               

 

Scientific Presentations 2011 and earlier

Presentation Title Conference Date
Combined Coxsackievirus A21 Oncolytic Virotherapy and Chemotherapy for the Treatment of Malignant Melanoma POSTER 6th Australian Society of Virology Meeting, Australia. 4-8 December 2011
The Oncolytic Activity of Low Pathogenic Human Enteroviruses in Combination with Carboplatin for the Treatment of Malignant Glioma Australasian Virology Society Meeting, Kingscliff, Australia. 2 December 2011
Establishment of an Orthotopic Murine Lung Cancer Model For The Testing of Coxsackievirus A21 (CVA21) Virotherapy Australasian Virology Society Meeting, Kingscliff, Australia. 2 December 2011
CAVATAKTM (Coxsackievirus A21) displays potent oncolytic activity in BRAFV600E mutant melanoma cells resistant to selective BRAF kinase inhibitors 8th International Congress of The Society for Melanoma Research, Tampa, Florida. 9-11 November 2011
Oncolytic Activity of Coxsackievirus A21 (CAVATAKTM) in Human Lung Cancer WCLC 14th World Conference on Lung Cancer 3-7 July 2011
Oncolytic Activity of Coxsackievirus A21 (CAVATAK) in Human Pancreatic Cancer World Congress for Gastrointestinal Cancers, Barcelona, Spain, 23 June 2011
A Phase I, open label, cohort study of two doses of Coxsackievirus A21 given intratumorally in Stage IV melanoma American Society of Clinical Oncology 5 June 2011
Coxsackievirus A21 as an oncolytic agent for the control of cancer 4th Annual World Cancer Congress, Dalian, China 22-25 May 2011
Oncolytic activity of Coxsackievirus A21 (CAVATAK) in human pancreatic cancer 6th International Conference on Oncolytic Viruses as Cancer Therapeutics April 2011
Phase I evaluation of the Intralesional administration of the Oncolytic Picornavirus, Coxsackievirus A21 (CAVATAKTM) in patients with late stage melanoma International Melanoma Conference Nov 2010.
Coxsackievirus A21 as an oncolytic virotherapy agent against malignant glioma EUROPIC 2010: XVI Meeting in St Andrews, Scotland September 2010
Phase I studies of intravenous and intratumoural administration of oncolytic Coxsackievirus A21 (CAVATAKTM) in patients with advanced cancer The Fifth International Meeting on Replicating Oncolytic Virus Therapies, Banff, Canada March 2009
Immune response to an oncolytic human picornavirus, Coxsackievirus A21 (CAVATAKTM) in patients with late stage melanoma Conference on Translational Cancer Research, Newcastle, NSW Sept 2008
Coxsackievirus A21 oncolytic virotherapy as a novel treatment for malignant glioma Conference on Translational Cancer Research, Newcastle, NSW Sept 2008
CAVATAKTM as an oncolytic virotherapy agent for human cancers 4th International Conference on Oncolytic Viruses as Cancer Therapeutics, Scottsdale, Arizona, USA, March 2007
A common cold producting virus with anti-cancer properties against Human Mestastatic Breast Cancer 4th International Conference on Oncolytic Viruses as Cancer Therapeutics, Scottsdale, Arizona, USA, March 2007
Low Pathogenic Enteroviruses as Novel Oncolytic Agents Against Human Prostate Cancer Northern Lights EUROPIC XIVth Meeting of the European Study Group on the Molecular Biology of Picornaviruses, November 2006
Coxsackievirus A21 as an Oncolytic Virotherapy Agent for Human Cancers Northern Lights EUROPIC XIVth Meeting of the European Study Group on the Molecular Biology of Picornaviruses, November 2006
The Human Enterovirus, Coxsackievirus A21, exhibits Oncolytic Activity Across a Spectrum of Cancer Types. AACR 96TH Annual Meeting, Anaheim, California, USA October 2005
Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).